Clinical trial · no report yet · Phase 3
ACTION-1
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- NCT05477576 ↗
- Active not recruiting
- RayzeBio, Inc.
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET
- Interventions
- RYZ101; Everolimus; Sunitinib; Octreotide; Lanreotide
- Arms
- Phase 1b - RYZ101 · Experimental
- Phase 3 - RYZ101 · Active comparator
- Phase 3 - Standard of Care · Active comparator
- Phase 3 - RYZ101, PK/ECG Substudy adhoc subcohort · Active comparator
- Enrollment
- 343
- Primary outcomes
- Phase 1b: RP3D
- Phase 3: PFS as determined by BICR
- Sponsor
- RayzeBio, Inc.
- Start
- Mar 24, 2022
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05477576 · updated Oct 5, 2026
Publications
linked from the registry- Taunk NK, Escorcia FE, Lewis JS, Bodei L. Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets. Cancer J. 2024 May-Jun 01;30(3):218-223. doi: 10.1097/PPO.0000000000000720. PubMed 38753757